XARTEMIS XR’s release profile combines Mallinckrodt’s newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed’s advanced Acuform drug delivery technology. The drug is the first
Qudexy XR is indicated as initial monotherapy in patients ten years of age and older with POS or primary generalized tonic-clonic seizures. The once-daily, broad-spectrum antiepileptic drug is
The solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. IGI
The trial, which evaluated the efficacy of two dose regimens of mepolizumab, also met its primary endpoint of reduction in the frequency of exacerbations. Throughout the trial, patients
Under the deal, Medinet will license its new cell therapy technology to TC Biopharm for clinical development in the UK and Europe. The deal and subsequent commercialization is
ND0612 is being developed for continuous subcutaneous administration through a patch pump and is designed to provide steady levodopa blood levels for the treatment of PD. The company
UCB’s research arm UCB NewMedicines has used a new approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly
The product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4mg/mL, of Hospira. The injection is indicated for the
The patent, titled ‘Methods and Compositions for Oral Administration of Exenatide’, covers oral exenatide compositions made using Oramed’s proprietary technology, including its ORMD-0901 oral exenatide capsule. The company
DME occurs due to fluid leakage into the area of the retina. The sight-threatening condition occurs in type 1 and type 2 diabetes patients. ThromboGenics’ new biotherapeutics are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.